

STANDARD OPERATING PROCEDURE

	SOP No.: 001	Version: 1.2
Whole Blood Basophil Activation Assay	Effective Date: 23April2014	Page: 1 of 6
Trial Number (if applicable):ITN050AD		

Document Approval	
Document Author:	
Barbara Nagaraj, Director, Mechanistic Operations	Date
Gideon Lack, Head of Department of Paediatric Allergy, King's College London	
Alexandra Santos, Clinical Research Fellow, King's College London	
Approval:	
	5 /
Deborah Phippard, Executive Director Biomarker & Discovery Research	Date
Approval:	
Kari Nadeau, MD, PhD, Stanford University	Date
Approval:	
	Date



STANDARD OPERATING PROCEDURE

Title:	SOP No.: 001	Version: 1.2
Whole Blood Basophil Activation Assay	Effective Date: 23April2014	Page: 2 of 6
Trial Number (if applicable):ITN050AD		

1 Purpose

To describe the procedure for executing the basophil activation assay using whole blood samples to support clinical trial ITN050AD at the Stanford Nadeau laboratory.

2 Definitions and Abbreviations

RPMI-1640	Roswell Park Memorial Institute medium, is a general purpose media with a broad range of applications for mammalian cells, especially hematopoietic cells
BD Pharmlyse	A buffered, concentrated (10X) ammonium chloride-based lysing reagent.
PBS	Phosphate buffered saline
EDTA	Ethylenediaminetetraacetic acid – chelating agent
FACS tube	Tubes compatible with flow cytometer
WB	Whole Blood
BSA	Bovine Serum Albumin
PE	Peanut extract

3 Equipment and Materials

Reagents:

- RPMI 1640
- BD Pharmlyse (made from 10X stock with dH₂O)
- PBS + 20 mM EDTA
- Staining Buffer: PBS + 2 mM EDTA + 0.5% BSA



STANDARD OPERATING PROCEDURE

Title:	SOP No.: 001	Version: 1.2
Whole Blood Basophil Activation Assay	Effective Date: 23April2014	Page: 3 of 6
Trial Number (if applicable):ITN050AD		

Monoclonal antibodies:

Vendor	Reagent	Ab Clone Name	Catalog Number(s)
eBiosciences	aCD123-FITC	6H6	11-1239-42
BioLegend	aCD203c-PE	NP4D6	324606 (100 test)
BioLegend	aHLADR-PerCP	L243	307628 (100 test)
BioLegend	aCD63-APC	MEM-259	312010 (100 test)

- Stimulants (prepared in RPMI immediately before use)
- 2 μg/mL Anti-IgE (final concentration 1 μg/mL)
- 2 μM fMLP (final concentration 1 μM)
- 5 μg/mL Anti-FceRI (final concentration 2.5 μg/mL)
- Peanut extract from the Golden Peanut Company (final top concentration 10 μg/ml, prepare 6 dilutions starting at 20 μg/mL and serially diluting 10-fold). Note that this preparation is from the same supplier as that used to dose participants in the IMPACT ITN050AD trial.

Equipment

- Bench top refrigerated centrifuge capable of 800 x g
- LSR II flow cytometer



STANDARD OPERATING PROCEDURE

Title: Whole Blood Basophil Activation Assay	SOP No.: 001	Version: 1.2
	Effective Date: 23April2014	Page: 4 of 6
Trial Number (if applicable):ITN050AD		

4 Procedures

1. Label the required number of round-bottom, polypropylene FACS tubes.

		Stimulant	
Tube	Cells	(100µl)	Antibodies
1		RPMI	
2		PE 0.2 ng/mL	
3		PE 2 ng/mL	
4		PE 20 ng/mL	aCD123-FITC
5		PE 200 ng/mL	aCD203c-PE
6	100µl	PE 2000 ng/mL	aHLADR-PerCP
7	WB	PE 20000 ng/mL	aCD63-APC
8		algE 2 μg/mL	
9		fMLP 2μM	
10		aFcεRI 5μg/mL	
			aCD123-FITC, aHLADR-PerCP
Isotype control		RPMI	IgG-PE, IgG-APC



Biomarker & Discovery Research STANDARD OPERATING PROCEDURE

Title:	SOP No.: 001	Version: 1.2
Whole Blood Basophil Activation Assay	Effective Date: 23April2014	Page: 5 of 6
Trial Number (if applicable):ITN050AD		

- 2. Dilute stimulants to the appropriate concentration (above) in RPMI (Peanut protein fMLP, anti-IgE and aFcɛRI)
- 3. Transfer 100 µL of RPMI to tube 1 and isotype control
- 4. Transfer 100 μL of appropriate stimulant to tubes 2-10 as above.
- 5. Transfer 100 μ L of patient whole blood to each tube (total volume = 200 μ L).
- 6. Incubate for 30 minutes at 37°C (5% CO2) in an incubator.
- 7. During the incubation, prepare ice bucket and mAb staining cocktail: 2.5μl CD123FITC + 5μL HLADR-PerCP + 10μl CD203c-PE + 5μl CD63-APC per condition/tube.
- 8. Add 20 µL cold (4°C) 20 mM EDTA to each tube and put the tubes on ice to stop degranulation.
- 9. Stain cells by adding 22.5µL of the prepared Ab cocktail to tubes 1-10
- 10. For isotype control, add 2.5μl CD123-FITC + 5μl HLADR-PerCP + 2.5μl PE-isotype + 10μL APC-isotype
- 11. Incubate all tubes at 4°C for 30 minutes in the dark
- 12. Add 3 mL cold (4°C) staining buffer to each tube & centrifuge @ 300xg for 5 minutes at 4°C.
- 13. Decant supernatant very carefully as the pellet will be loose.
- 14. Add 4 mL of 1x lysis buffer (BD Pharmlyse) with serological pipette while vortexing at a low speed.
- 15. Incubate at room temperature in the dark for 15 minutes.
- 16. After incubation, centrifuge @ 800 x g for 10 minutes at 4°C.



STANDARD OPERATING PROCEDURE

Title:	SOP No.: 001	Version: 1.2
Whole Blood Basophil Activation Assay	Effective Date: 23April2014	Page: 6 of 6
Trial Number (if applicable):ITN050AD		

- 17. Decant supernatants carefully, add 3 mL of cold staining buffer to each tube and centrifuge @ 500xg for 5 minutes at 4°C.
- 18. Decant supernatants carefully and resuspend in 200 μ L of staining buffer. Transfer to a 96 well plate for acquisition on the LSR-II.
- 19. Store at 4°C in the dark until ready to acquire (same day is optimal, acquisition within 24 hours is acceptable).

5 Attachments and References

6 History of Revision

Version	Effective Date	Section	Description of Revisions/Justifications
1.0	20May2013	3 Reagents	Updated source of peanut flour from Byrd to Golden
			Peanut Co